Daniela De Florentiis

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience.

Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience.

Journal: Intensive care medicine

Published: August 07, 2015

Influenza vaccination in the elderly: why are the overall benefits still hotly debated?

Influenza vaccination in the elderly: why are the overall benefits still hotly debated?

Journal: Journal of preventive medicine and hygiene

Published: February 11, 2015

Clinical and therapeutic aspects of candidemia: a five year single centre study.

Clinical and therapeutic aspects of candidemia: a five year single centre study.

Journal: PloS one

Published: January 29, 2015

Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults.

Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults.

Journal: Human vaccines & immunotherapeutics

Published: December 09, 2014

Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients.

Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients.

Journal: Intensive care medicine

Published: November 17, 2014

Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Journal: Human vaccines & immunotherapeutics

Published: January 09, 2013

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.

Journal: Human vaccines & immunotherapeutics

Published: January 09, 2013

Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

Journal: Human vaccines & immunotherapeutics

Published: January 08, 2013

Bacterial carriage and respiratory tract infections in subjects > or = 60 years during an influenza season: implications for the epidemiology of community acquired pneumonia and influenza vaccine effectiveness.

Bacterial carriage and respiratory tract infections in subjects > or = 60 years during an influenza season: implications for the epidemiology of community acquired pneumonia and influenza vaccine effectiveness.

Journal: Journal of preventive medicine and hygiene

Published: December 18, 2012

Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.

Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.

Journal: Journal of preventive medicine and hygiene

Published: December 18, 2012

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.

Journal: Human vaccines & immunotherapeutics

Published: July 27, 2012

Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.

Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.

Journal: Vaccine

Published: December 21, 2011

Showing 1-12 of 14

Last Updated: 09/26/2026